ArTificial inTelligence-based RAdiogenomics in Colon Tumors

The goal of this clinical trial is to develop an artificial intelligence-based model to assess radiogenomics signature of colon tumor in patients with stage II-III colon cancer. The main question it aims to answer is: • Can artificial intelligence-based algorithm of radiomics features combined with clinical factors, biochemical biomarkers, and genomic data recognise tumor behaviour, aggressiveness, and prognosis, identifying a radiogenomics signature of the tumor? Participants will * undergo a preoperative contrast-enhanced CT examination; * undergo surgical excision of colon cancer * undergo adjuvant therapy if deemed necessary based on current guidelines

Sex

All

Minimum age

18 Years

Inclusion Criteria:

* patients with pathologically proven stage II and stage III colon cancer;
* availability of a CT scan with portal-venous phase at the time of diagnosis;
* availability of immunohistochemical panel

Exclusion Criteria:

* patients with no CT images prior to surgical resection;
* patients with CT scans characterized by motion artifacts preventing radiomics analysis

• BACKGROUNDMiller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016 Jul;66(4):271-89. doi: 10.3322/caac.21349. Epub 2016 Jun 2. PMID 27253694
• BACKGROUNDBosman FT. Tumor Heterogeneity: Will It Change What Pathologists Do. Pathobiology. 2018;85(1-2):18-22. doi: 10.1159/000469664. Epub 2017 May 9. PMID 28482346
• BACKGROUNDChakraborty S, Hosen MI, Ahmed M, Shekhar HU. Onco-Multi-OMICS Approach: A New Frontier in Cancer Research. Biomed Res Int. 2018 Oct 3;2018:9836256. doi: 10.1155/2018/9836256. eCollection 2018. PMID 30402498
• BACKGROUNDChen S, Zhang N, Shao J, Wang T, Wang X. Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer. J Cancer. 2019 Jan 1;10(3):697-707. doi: 10.7150/jca.28494. eCollection 2019. PMID 30719168
• BACKGROUNDHondermarck, H., Cancer Omics: A Special Issue to Highlight Where We Are Heading. Proteomics, 2018. 18(24): p. e180038
• BACKGROUNDHuang L, Brunell D, Stephan C, Mancuso J, Yu X, He B, Thompson TC, Zinner R, Kim J, Davies P, Wong STC. Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction. Bioinformatics. 2019 Oct 1;35(19):3709-3717. doi: 10.1093/bioinformatics/btz109. PMID 30768150
• BACKGROUNDLong NP, Jung KH, Anh NH, Yan HH, Nghi TD, Park S, Yoon SJ, Min JE, Kim HM, Lim JH, Kim JM, Lim J, Lee S, Hong SS, Kwon SW. An Integrative Data Mining and Omics-Based Translational Model for the Identification and Validation of Oncogenic Biomarkers of Pancreatic Cancer. Cancers (Basel). 2019 Jan 29;11(2):155. doi: 10.3390/cancers11020155. PMID 30700038